Literature DB >> 22559155

A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder.

Paul Hammerness1, Randall Zusman, David Systrom, Craig Surman, Aaron Baggish, Mary Schillinger, Rachel Shelley-Abrahamson, Timothy E Wilens.   

Abstract

OBJECTIVES: Due to concerns about the safety of stimulants for ADHD, novel assessments of the cardiopulmonary impact of these agents are needed.
METHODS: An open design of lisdexamfetamine (LDX) in 15 adults with DSM-IV ADHD. Following a psychiatric evaluation and medical history, subjects underwent echocardiography (TTE) and cardiopulmonary exercise testing (CPET). LDX was titrated to 70 mg daily over 6 weeks, followed by monthly visits to 6 months. Change in TTE and CPET measures were examined following up to 6 months of LDX.
RESULTS: At endpoint, there were no significant alterations in indices of cardiac systolic performance, or in metabolic and ventilatory variables at maximum exertion (P values >0.05). We found significant mean changes in resting LV systolic dimension and Doppler diastolic indices. Change in heart rate recovery at 1 min met statistical significance (P = 0.05).
CONCLUSIONS: We did not detect clinically meaningful changes in cardiac structure and function or in metabolic and ventilatory variables at maximum exertion in ADHD adults receiving open LDX. The clinical significance of changes in resting LV dimension and indices of diastolic function are not in the direction of cardiomyopathy. Future large sample controlled study can examine these findings, as well as stimulants' impact on heart rate recovery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22559155     DOI: 10.3109/15622975.2012.678884

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  9 in total

1.  Impact of Stimulant Medication Use on Heart Rate and Systolic Blood Pressure During Submaximal Exercise Treadmill Testing in Adolescents.

Authors:  Arthur N Westover; Paul A Nakonezny; Bryon Adinoff; Edson Sherwood Brown; Ethan A Halm
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-09-14       Impact factor: 2.576

Review 2.  Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Authors:  Jose Martinez-Raga; Carlos Knecht; Nestor Szerman; María I Martinez
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

3.  Heart Rate Recovery and Systolic Blood Pressure Recovery After Maximal Exercise in Prevalent Users of Stimulant Medications.

Authors:  Arthur N Westover; Paul A Nakonezny; Carolyn E Barlow; Bryon Adinoff; E Sherwood Brown; Ethan A Halm; Wanpen Vongpatanasin; Laura F DeFina
Journal:  J Clin Psychopharmacol       Date:  2016-06       Impact factor: 3.153

Review 4.  Lisdexamfetamine: A Review in ADHD in Adults.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2016-04       Impact factor: 5.749

Review 5.  Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults.

Authors:  Eric Mick; David D McManus; Robert J Goldberg
Journal:  Eur Neuropsychopharmacol       Date:  2012-07-15       Impact factor: 4.600

6.  Update on optimal use of lisdexamfetamine in the treatment of ADHD.

Authors:  Vishal Madaan; Venkata Kolli; Durga P Bestha; Manan J Shah
Journal:  Neuropsychiatr Dis Treat       Date:  2013-07-22       Impact factor: 2.570

Review 7.  A systematic review of the safety of lisdexamfetamine dimesylate.

Authors:  David R Coghill; Beatriz Caballero; Shaw Sorooshian; Richard Civil
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

8.  A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects.

Authors:  James Ermer; Patrick Martin; Mary Corcoran; Yumiko Matsuo
Journal:  Neuropsychopharmacol Rep       Date:  2019-11-25

Review 9.  Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder.

Authors:  Jadwiga Najib; Dexter Wimer; Julie Zeng; Kristina W Lam; Natalya Romanyak; Eva Paige Morgan; Anu Thadavila
Journal:  J Cent Nerv Syst Dis       Date:  2017-08-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.